ALX Oncology Names Jeff Knight as Chief Development Officer ALX Oncology appointed Jeff Knight as Chief Development Officer on Apr 13, 2026; this hire could accelerate BD activity ahead of 2027 program milestones.

ALX Oncology Names Jeff Knight as Chief Development Officer: ALX Oncology appointed Jeff Knight as Chief Development Officer on Apr 13, 2026; this hire could accelerate BD activity ahead of 2027… 👈 Read full analysis #ALXOncology #Leadership #BusinessDevelopment #ClinicalTrials #HealthcareNews